



BioAlliance Pharma filed an appeal to the French Supreme Court contesting a preliminary procedural decision on jurisdiction in the arbitration against SpePharm and SpeBio

Paris, June 1, 2011 – The proceedings to the arbitral tribunal are still at a preliminary stage concerning the scope of its jurisdiction. This tribunal will have to rule on the relief sought by BioAlliance Pharma and the counterclaims of SpePharm and SpeBio.

BioAlliance Pharma announces today that it has filed an appeal to the French Supreme Court on a procedural matter in this arbitral proceedings that it had initiated against SpePharm and SpeBio. In this arbitration, BioAlliance Pharma argues that SpePharm and SpeBio (the common subsidiary which is managed by SpePharm and which was created at the time in order to market Loramyc®) breached their contractual obligations. These breaches resulted in a delay in the marketing of Loramyc® and which compelled BioAlliance to rescind the contracts in question.

BioAlliance Pharma contests the decisions rendered on the issue of the scope of the jurisdiction of the arbitral tribunal.

These decisions or any public declaration of SpePharm on this subject have no bearing on the merits of the case and the decisions that will be issued in the future once the question of jurisdiction is finally decided.

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products — BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU US, Korea)

Setofilm® (prevention and treatment of nausea and vomiting post chemo-radiotherapy and post operative) - Registered in EU

Sitavir® (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products

Livatag® (Doxorubicin Transdrug™) in primary liver cancer: Phase II results on survival

Clonidine Lauriad™ (mucositis): Phase II on going

AMEP® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, CEO

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Judith Greciet, COO

Tel +33 1 45 58 70 61

judith.greciet@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com